Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Trial details
- Registry ID
- NCT05727904
- Drugs studied
- Lifileucel plus Pembrolizumab, Pembrolizumab with Optional Crossover Period